Notch Therapeutics – a new company with a revolutionary allogeneic ('off the shelf') T cell technology
Aligned with our vision to invent the future of health care, Sunnybrook – along with co-founders CCRM, University of Toronto (UoT), Toronto Innovation Acceleration Partners (TIAP) and investor Lumira Ventures – has created Notch Therapeutics, a new company in the emerging field of T cell therapy.
Notch looks to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited T cells from stem cells on an industrial scale, efficiently making high quality and clinically robust T cell therapies.
